Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3747/co.22.2447 http://scihub22266oqcxt.onion/10.3747/co.22.2447 C4462531!4462531!26089720     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Oncol 2015 ; 22 (3): 211-9 Nephropedia Template TP {{tp|p=26089720|t=2015. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline |pdf=|usr=}}{{26089720}} gab.com Text Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline JO: Curr Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26089720 #FOAvip Background: Systemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cancer Care Ontario?s Program in Evidence-Based Care. Methods: The literature between 2006 and April 2014 in the medline and embase databases, the Cochrane Database of Systematic Reviews (Issue 4, 2014), the Cochrane Central Register of Controlled Trials (Issue 3, 2014), relevant guideline databases, and conference proceedings of the American Society of Clinical Oncology (2007?2013) was searched. A working group developed draft guidelines and incorporated comments and feedback from internal and external reviewers. Results: Four phase iii randomized controlled trials met the inclusion criteria for the review and provided the basis for draft recommendations. Feedback was obtained from Ontario practitioners and others abroad, which led to modifications to the draft recommendations. Three key recommendations were developed. Conclusions: The working group concluded that all patients should be offered the opportunity to participate in appropriate randomized clinical trials. Cisplatin?paclitaxel, cisplatin?vinorelbine, cisplatin?gemcitabine, and cisplatin?topotecan are recommended combinations for this patient population. The substitution of carboplatin for cisplatin in the foregoing combinations can also be recommended because carboplatin is associated with fewer adverse effects and greater ease of administration. Selection of combination chemotherapy will depend on the toxicity profile, patient preference, and other factors. Finally, bevacizumab in combination with cisplatin?paclitaxel or carboplatin?paclitaxel is recommended for a specific subset of the target population as outlined in Gynecologic Oncology Group study 0240. Twit Text FOAVip Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline ????Curr Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26089720 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26089720 #FOAvip English Wikipedia <ref>{{Cite pmid|26089720}}</ref> Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline #MMPMID26089720 Hirte H; Kennedy E; Elit L; Fung Kee Fung M Curr Oncol 2015[Jun]; 22 (3): 211-9 PMID26089720show ga Background: Systemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cancer Care Ontario?s Program in Evidence-Based Care. Methods: The literature between 2006 and April 2014 in the medline and embase databases, the Cochrane Database of Systematic Reviews (Issue 4, 2014), the Cochrane Central Register of Controlled Trials (Issue 3, 2014), relevant guideline databases, and conference proceedings of the American Society of Clinical Oncology (2007?2013) was searched. A working group developed draft guidelines and incorporated comments and feedback from internal and external reviewers. Results: Four phase iii randomized controlled trials met the inclusion criteria for the review and provided the basis for draft recommendations. Feedback was obtained from Ontario practitioners and others abroad, which led to modifications to the draft recommendations. Three key recommendations were developed. Conclusions: The working group concluded that all patients should be offered the opportunity to participate in appropriate randomized clinical trials. Cisplatin?paclitaxel, cisplatin?vinorelbine, cisplatin?gemcitabine, and cisplatin?topotecan are recommended combinations for this patient population. The substitution of carboplatin for cisplatin in the foregoing combinations can also be recommended because carboplatin is associated with fewer adverse effects and greater ease of administration. Selection of combination chemotherapy will depend on the toxicity profile, patient preference, and other factors. Finally, bevacizumab in combination with cisplatin?paclitaxel or carboplatin?paclitaxel is recommended for a specific subset of the target population as outlined in Gynecologic Oncology Group study 0240. äSystemic therapy for recurrent, persistent, or metastatic cervical can(epmc).pdf DeepDyve Pubget Overpricing